Aktienanalyse zu Calidi Biotherapeutics Inc (CLDI)CLDICalidi Biotherapeutics Inc

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Calidi Biotherapeutics is not a good buy right now due to its severe financial losses and delisting risk. The stock has a current price of $0.68, down 96.40% year-to-date, and has a negative forward P/E ratio of 0, indicating no earnings expectations. Additionally, the company faces a compliance notice from the NYSE due to stockholders' equity below the required $4 million, which poses a significant risk of delisting.